A 68-year-old woman (patient 1) was diagnosed in October 2010 with a melanoma....A point mutation (c.1790 T>G), L597R, was identified in both lymph node and subcutaneous metastases (not shown)...the patient (patient 1) was treated with 480 mg vemurafenib twice per day (because of a cutaneous drug-induced reaction with 960 mg vemurafenib twice per day)...The duration of response was more than 4 months....Here we show that BRAF inhibitors can be effective for patients with melanomas that harbor a BRAF L597R mutation.